Rana Al-Hrout/LinkedIn
Nov 7, 2026, 11:37
Rana Al-Hrout: ITP Treatment in 2026 – Moving Beyond Platelet Counts
Rana Al-Hrout, Clinical Pathology-Hematology Specialist at Ministry of Health – Jordan, shared a post on LinkedIn:
“The Evolving ITP Treatment Landscape – 2026
The management of Immune Thrombocytopenia (ITP) continues to evolve toward more individualized and patient-centered treatment strategies.
Key developments include:
- Corticosteroids: Emphasis on short treatment courses and minimizing long-term exposure.
- Combination therapy: Earlier consideration of TPO-receptor agonists and Rituximab in selected patients.
- Targeted therapies: Expanding treatment options, including SYK and BTK inhibitors.
- Patient-centered care: Focusing on bleeding prevention, treatment burden, and quality of life.
The key message:
Successful ITP management goes beyond platelet counts. It aims for sustainable disease control and improved patient outcomes.”
Other posts featuring Rana Al-Hrout on Hemostatis Today.
-
Nov 7, 2026, 09:00Charlotte Guzzo: MHRA Approves Gene Editing for Younger Children
-
Nov 7, 2026, 08:47Mohammedbaqer Ali Al-Ghuraibawi: Rethinking Aspirin Use After Acute Coronary Syndrome
-
Nov 7, 2026, 08:28Shayan Mohammadmoradi: Targeting Inflammation in Atherosclerosis
-
Nov 7, 2026, 08:15Abdul Mannan: Severe Coagulopathy and the Importance of Drug History
-
Nov 7, 2026, 07:59Zahra Ghasemi: Plasma Self-Sufficiency – Are We Measuring Supply or Actual Need?
-
Nov 7, 2026, 06:11Bruno Matos Santos: Gastric and Oesophageal Necrosis Due to Extensive Venous Thrombosis
-
Nov 7, 2026, 05:57Nawsherwan Mohammad: Hypercoagulability and Pulmonary Hypertension in Beta Thalassemia
-
Nov 7, 2026, 05:45Andrew Davies: HIDDEN 2 Rethinking Thromboprophylaxis in Hospice Care
-
Nov 7, 2026, 05:32Cancer, Catheters and Outcomes in Upper Extremity DVT – JTH